These results showed that patients with a FLT3 mutation had lower expression of CXCR3, CXCR5, and CXCR6 transcripts than that in mutation-negative patients, suggesting a possible anti-cancer effect of CXCR3/5/6 in AML. This evidence concerns the gene CXCR6 and cancer.